Background and purpose: More than one third of American adults are obese. Extreme obesity is rapidly rising. Nine medications are approved for weight loss yet they remain underutilized with the focus primarily on lifestyle modifications. The objective was to determine current prescribing patterns and attitudes of weight loss medications in the management of obesity among primary care providers (PCPs). Methods: PCPs were surveyed to determine practice patterns, attitudes, barriers, and facilitators for prescribing weight loss medications. Conclusions: Ninety-four surveys were analyzed. Seventy-six percent of all PCPs did not prescribe weight loss medications for long-term weight loss and 58% of PCPs had negative perceptions of pharmacotherapy. Differences existed between prescribing patterns and attitudes of advanced practice clinicians and physicians. Safety concerns were the greatest barrier. Having 2+ comorbidities and severe obesity were facilitators for prescribing weight loss medications. Underutilization of pharmacotherapy suggests that PCPs may not have sufficient knowledge about medication safety profiles and efficacy. Delaying treatment until patients have reached a high level of morbidity may be less efficacious than earlier treatment. Implications for practice: Education regarding effectiveness and risks of weight loss medications for obesity management is needed and earlier interventions with pharmacotherapy may prevent significant morbidity and mortality.
Introduction
The prevalence of obesity in the United States is high. (Sturm & Hattori, 2013) .
The direct and indirect costs attributed to obesity in the United States are staggering. While direct medical costs may include prevention, diagnostic, and treatment services associated with obesity and obesity-related diseases, indirect medical costs may include premature mortality, higher disability insurance premiums, and productivity loss because of obesity (Hammond & Levine, 2010) . Overall, the annual medical burden of obesity has risen to 9.1% of all medical spending with approximately $147-$210 billion per year spent on obesity-related healthcare costs (Trust for America 's Health & Robert Wood Johnson Foundation, 2017) .
Obesity is a significant health concern. The disease substantially increases the risk for morbidity and mortality because of the wide range of associated comorbidities. According to CDC (2016a), obesity-related conditions comprise some of the leading causes of preventable death, including cardiovascular disease, stroke, type 2 diabetes, and certain types of cancer. Overall, as BMI rises, the risk for multimorbidity (co-occurrence of multiple long-term diseases) increases in both men and women. The prevalence of multimorbidity in men and women with normal weight is 23% and 28%, respectively, rising to 44% in men and 51% in women with extreme obesity . Weight loss of 5%-10% of total baseline body weight has been shown C 2017 American Association of Nurse Practitioners to decrease cardiovascular disease risk factors, including lowering blood pressure and blood cholesterol, as well as preventing or delaying the development of type 2 diabetes by reducing blood sugars (CDC, 2016b) .
Despite the concerning obesity epidemic, appropriate and consistent management of obese individuals in primary care settings remains varied (Bleich, Pickett-Blakely, & Cooper, 2011; Shiffman et al., 2009) . Current clinical guidelines from the U.S. Preventive Services Task Force recommend that all adult patients be screened for obesity and individuals with BMI ࣙ30kg/m 2 should be offered or referred to intensive, multicomponent behavioral interventions (Moyer, 2012) . Regardless of these recommendations, several cross-sectional studies have shown that not only are obese individuals not being consistently diagnosed, weight loss counseling by primary care providers (PCPs) is also infrequent, inconsistent, and suboptimal (Bleich et al., 2011 , Shiffman et al., 2009 Smith et al., 2011) . Weight loss counseling strategies may include discussion of obesity diagnosis and its associated risk factors, advice regarding lifestyle interventions such as diet and/or exercise, or recommendations for pharmacotherapy or bariatric surgery. When weight loss counseling is incorporated into clinical practice, studies have found that lifestyle interventions are the foundation of PCPs' recommendations. Although pharmacotherapy and bariatric surgery are available and effective weight loss interventions, they are often not included or rarely recommended to individuals with obesity (Ferrante, Piasecki, OhmanStrickland, & Crabtree, 2009; Shiffman et al., 2009) .
Lifestyle interventions alone are not particularly successful in providing long-term weight maintenance because of behavioral and environmental pressures as well as biological mechanisms induced by weight loss (Booth, Prevost, Wright, & Gulliford, 2014; Johannsen et al., 2012) . Although many individuals are able to lose weight initially with diet and exercise, more than one third of weight lost is regained within year 1 (MacLean, Bergouignan, Cornier, & Jackman, 2011) . The most recent guidelines for obesity management recommend considering pharmacotherapy as an adjunct to lifestyle interventions for individuals with BMI ࣙ 30 kg/m 2 or BMI ࣙ27 kg/m 2 with ࣙ1 obesityassociated comorbid condition (Jensen et al., 2014) . The U.S. Food and Drug Administration (FDA) has currently approved five medications for long-term weight loss therapy. The addition of pharmacotherapy as an adjunct to traditional lifestyle approaches has shown to be an effective treatment option for weight loss in obese individuals (Khera et al., 2016; . When combined with lifestyle interventions, weight loss medications have resulted in clinically significant weight loss of 5%-10% (Gadde et al., 2011; Khera et al., 2016; Smith et al., 2010; 
Study design and methods
This study was reviewed and approved by the Internal Review Board prior to study procedures. Inclusion criteria consisted of the ability to read and write in English, self-identified as a PCP, and provided health care for individuals who are ࣙ18 years of age. Exclusion criteria included PCPs who provided patient care in specialty practices that included bariatric health, endocrinology, and/or cardiology.
Data collection
A convenience sample of primary care nurse practitioners (NPs), physician assistants (PAs), and physicians (MDs) were recruited using online list serves from regional professional organizations and on-site at one organization's annual conference in northeastern United States. Potential participants during on-site data collection received a hard copy invitation and survey and potential online participants received an electronic invitation and survey. Participants' completion of the distributed survey served as passive informed consent. Data were entered into LimeSurvey statistical software (version 2.55) (Schmitz & LimeSurvey Project Team, 2015) .
Survey development
The study survey was formulated and adapted based on a review of the literature reflecting current obesity management and barriers and facilitators for weight loss counseling. Two content experts reviewed the survey to ensure clarity and content validity. The survey contained 24 questions in which PCPs were asked to express their impressions and use of obesity pharmacotherapy. Demographic data including ethnicity, type of PCP (i.e., NP, MD, or PA), years in practice, primary specialty, patient population, and location of clinical practice were collected.
Analysis
PCP demographics were summarized using descriptive statistics and frequency tables. Inferential statistics were computed to assess attitudes and practice patterns around the use of weight loss medications. Pearson chi-square tests were computed to determine between group (physician vs. advanced practice clinician) differences in demographics, attitudes, and practice patterns. McNemar tests were used to compare the recommended use of each weight loss medication to its effectiveness. Open-ended questions were transcribed using categorical data. For all analyses, a p-value of <.05, two-sided, was established as statistically significant. SPSS v. 23 was used for data analysis (IBM Corp., 2015) .
Results
The survey reached approximately 964 PCPs. Of the nearly 964 PCPs approached, 105 PCPs completed the survey, resulting in a response rate of approximately 11%. Eleven of the respondents did not meet the study inclusion criteria, resulting in a final N = 94. The 94 respondents were self-identified as PCPs who worked primarily in family practice, internal medicine, adult primary care, and women's health. The demographic and practice characteristics of the respondents are summarized in Table 1 . Of the 94 respondents, 46 were MDs, 43 were NPs, and 5 were PAs. Because of the low response rate of PAs, responses from NPs and PAs were combined to a single provider group identified as advanced practice clinicians (APCs; N = 48).
Provider practice patterns around the use of weight loss medications for obesity management
Overall, 60% of the PCPs surveyed reported not prescribing weight loss medications for short-term weight loss therapy (<3 months). When grouped by provider type, APCs (46%) were prescribing weight loss medication more frequently than MDs (33%). Seventy-six percent of PCPs reported not prescribing weight loss medications for longterm therapy (ࣙ3 months). Prescribing patterns were not statistically different between provider groups for longterm therapy. Recommended medications are outlined in Table 2 in order based on frequency of prescribing. 
Provider attitudes of weight loss medications as a treatment for obesity
Fifty-eight percent of all PCPs reported "negative" and "very negative" impressions of pharmacotherapy as a treatment for obesity. Fifty-eight percent of APCs had a "neutral" to "very positive" impression of weight loss medications compared to 20% of MDs (p = .002). Seventyfive percent of MDs had a negative impression. Four percent of all PCPs felt weight loss medications were safe. Fifty-two percent of PCPs reported that some medications were safe and others were not safe. Seventy-three percent of APCs expected a >5% weight loss with the use of pharmacotherapy as an adjunct to lifestyle interventions compared to 50% of MDs (p = .044). Weight loss medications perceived as effective are outlined in Table 2 . While 40% of PCPs reported recommending orlistat, only 19% of PCPs reported orlistat as being effective for weight loss (Figure 1) .
Perceived barriers to the use of weight loss medications
The most frequently reported factors preventing PCPs from prescribing weight loss medications included fear of adverse events followed by fear of medication interactions (Table 3) . Cost and insurance coverage and lack of perceived effectiveness were third. Lack of time was the least important barrier to prescribing. Sixty percent of PCPs reported that concern of medication adverse events was a barrier to prescribing weight loss medications. Fortynine percent of PCPs reported that they would still not prescribe weight loss medications even if cost and insurance coverage were not significant barriers. There was a significant difference in responses between PCP types. Sixty-seven percent of APCs reported they would prescribe if cost/insurance were not barriers, compared to 34% of MDs (p = .02).
Perceived facilitators to the use of weight loss medications
The most frequently reported circumstance for recommending weight loss medication was if patients had 2+ comorbidities associated with obesity. The second most frequently reported circumstance was if patients had severe obesity (BMI ࣙ40 kg/m 2 ; Table 4 ). Failure to achieve goal weight with lifestyle interventions was third. Mild obesity (BMI = 30-34.9 kg/m 2 ) was identified as the least important factor for prescribing.
Discussion
Regardless of the high prevalence of obesity in the United States and its wide range of associated comorbidities, the PCPs in our study were hesitant to prescribe weight loss medications, particularly for long-term therapy. In general, over half of the PCPs had an overall unfavorable impression of pharmacotherapy as a treatment option for obesity, with MDs having a more negative impression than APCs. This, in addition to safety concerns and cost/insurance factors may explain why prescribing is low among all PCP types. Safety concerns were the most important barriers preventing PCPs from prescribing weight loss medications. Although long-term safety data have not been established for the combined agents approved for weight loss therapy, several drugs have been prescribed independently for many years; thus adverse side effects have been well established. Randomized controlled trials have examined drug efficacy and safety profiles. Reported common adverse side effects included gastrointestinal upset, neurological complaints (i.e., headache, dizziness, tremor, paresthesias), hypoglycemia, and elevated heart rate (Khera et al., 2016; . Serious adverse events were infrequently reported, comparable to placebo, varied depending on drug type, and included conditions such as cholelithiasis, cholecystitis, pancreatitis, severe hypoglycemia, and valvulopathy (Khera et al., 2016) . Although long-term trials have not been established, cardiac valvulopathy is generally associated with serotonin 2B receptor medications as opposed to the more selective serotonin 2C receptor medications recently approved (Smith et al., 2010) . While weight loss medications may impose risk, obesity is associated with significantly higher all-cause mortality relative to normal weight (Flegal, Kit, Orpana, & Graubard, 2013) . Thus, adverse effects of medications should be weighed against the benefits seen with weight loss medications. The PCPs' concerns about safety in the current study support previous research findings where physicians did not perceive available weight loss medications to be safe or effective (Glauser, Roepke, Stevenin, Dubois, & Ahn, 2015) . This suggests that PCPs may not have sufficient knowledge regarding the safety profiles of available medication options. Education of PCPs regarding the drugs' pharmacodynamics as well as risks for adverse side effects may facilitate increased confidence for prescribing, thus improving weight loss in obese patients.
Our results demonstrated that PCPs were more likely to prescribe weight loss medications to patients who were severely obese than to patients who were moderately or mildly obese. Although not specific to pharmacotherapy, our findings were consistent with previous studies that have reported BMI as a key factor in providing weight loss counseling to patients. Bleich et al. (2011) found that severely/morbidly obese individuals were significantly more likely to receive an obesity diagnosis and therefore were nearly six times more likely to receive weightreduction counseling than those who did not receive a diagnosis. Dutton et al. (2014) also found that a higher BMI (>35 kg/m 2 ) was associated with receiving more frequent weight loss counseling. According to our findings, it was evident that the degree of obesity was a pertinent factor for prescribing medication. There was a direct relationship between weight severity and increased prescribing. Obese patients who are not classified as severely obese may not be receiving recommendations from their PCPs about all available and effective treatment options, including pharmacotherapy. Further education of PCPs regarding when to initiate conversations with patients about weight loss pharmacotherapy, to include all levels of obesity, may lead to earlier interventions and prevention of worsening obesity and comorbid disease.
A modest 5%-10% weight reduction has been shown to improve lipids, decrease blood pressure, and reduce HbA 1c in patients with obesity (MacLean et al., 2015) . A systematic review showed that weight loss medications produced greater improvements in cardiometabolic risk factors than behavioral interventions alone . Other studies have shown that weight loss medications resulted in a more pronounced improvement in blood pressure, lipids, and glycemic control when used for patients with preexisting comorbid disease (Gadde et al., 2011) . Weight loss medications are approved for patients with a BMI of ࣙ30 kg/m 2 or a BMI ࣙ 27 kg/m 2 with one or more comorbidity in conjunction with a reducedcalorie diet and increased physical activity. The present study found that the most important facilitator for prescribing weight loss medications was patients' having two or more associated comorbidities. These findings suggest that PCPs may be intervening too late, when patients have reached the "severely obese" category and have already developed multiple comorbidities. Recommending and prescribing weight loss medications earlier in the disease process may be a more proactive approach to preventing the long-term sequelae of obesity.
Despite the overall low prescribing patterns for both short-and long-term weight loss therapy among all PCPs, APCs prescribed medication more frequently than MDs and were significantly more likely to prescribe medication when cost and insurance coverage were not pertinent factors. APCs also had a significantly more positive impression of pharmacotherapy as a treatment for obesity and higher expectations for weight loss than MDs. This suggests that PCPs with a higher expectation for weight loss and more positive impression may be more likely to prescribe weight loss medications for obesity. Previous research has shown that physicians' higher self-reported knowledge regarding weight loss medications was associated with fewer negative attitudes and more frequent recommendations of pharmacotherapy options (Ferrante et al., 2009) . With the majority of the APC group being NPs, our findings may be attributable to the philosophical lens of the nursing discipline. NPs traditionally take a holistic approach to patient-centered, context-based, diagnostic reasoning and care planning that is in line with nursing theory and philosophy (Hamric, Hanson, Tracy, & O'Grady, 2014) . Implementing a holistic approach that is patient-centered and highly individualized can be key to producing positive outcomes for patients with obesity.
We found that PCPs continue to be reluctant to recommend weight loss medications, despite their shown efficacy. Overall, antiobesity medications have shown higher efficacy in producing weight loss than lifestyle interventions alone. A review by Yanovski and Yanovski (2014) found that long-term obesity medications produced significant weight loss when used in combination with lifestyle modifications such as diet and exercise. Compared to placebo, additional weight loss at 1 year ranged from approximately 3% of baseline weight to 9%. Similarly a systematic review by Khera et al. (2016) found that all five medications approved for long-term weight loss therapy achieved at least 5% weight loss at 52 weeks, a significant improvement in weight maintenance.
Obesity management is multifactorial. Our study results suggest that obesity management for many patients does not extend past behavioral counseling and recommendations for diet and exercise. PCPs may not be appropriately educating their patients about the full spectrum of available and effective treatment options for obesity management. This may be because of low perceived effectiveness, safety concerns, and specific patient characteristics required. When considering the Chronic Care Model (Bodenheimer, Wagner, & Grumbach, 2002) , patients cannot be fully informed and engaged members in the decision-making process if they do not have fully informed and engaged PCPs. This study demonstrates the need for increased educational programs for PCPs regarding the indications, effectiveness, and potential risks associated with the use of weight loss medications. Continuing education may enhance PCP knowledge about weight loss medications and improve PCPs' ability to have informed conversations with patients and engage their patients in the decision-making process. Both PCPs and patients need accurate information about treatment options to collaboratively weigh the risks with the benefits. Additionally, earlier interventions with pharmacotherapy may prevent morbidity and mortality associated with obesity and its comorbidities. Differences exist in prescribing patterns between PCP types. Further research may be needed to better understand these differences in PCP attitudes and prescribing patterns.
Limitations
The current study is primarily limited by the small sample size and low response rate. Identifying list-serve numbers can be inexact; thus an exact response rate could not be determined. Causal inferences could not be made. PAs were not well represented in the study. Although patient motivation and cost/insurance coverage were included as potential barriers to prescribing weight loss medications, other patient-specific barriers including patients' willingness to take weight loss medications were not considered. This unexplored variable may impact prescribing patterns and should be further evaluated. Future studies should examine the effect that educational programs, focused on weight loss pharmacotherapy, have on PCP prescribing patterns.
Conclusion
This study demonstrates the need for supplementary educational programs to cultivate informed PCPs about the safe and effective use of weight loss medications as a component to obesity management. Educated PCPs can better inform and engage patients in shared decision-making with regards to obesity management. The overarching goal of PCPs is to reduce poor health outcomes and improve quality of life. Earlier use of pharmacotherapy in combination with lifestyle modifications may reduce the costly morbidity and mortality associated with obesity.
